39767 results about "Pharmacy medicine" patented technology

A scalable platform for orchestrating networks of specialized AI multi-agent networks that enables secure collaboration through token-based protocols and real-time result streaming with advanced dynamic chain-of-thought pruning. The central orchestration engine manages domain-specific agents, implementing sophisticated multi-branch reasoning with contribution-estimation layers that evaluate each agent's utility using Shapley value-inspired metrics. The system employs information-theoretic and gradient-based surprise metric to guide memory updates and dynamic reasoning expansion, preventing local minima stagnation while preserving valuable insights through adaptive forgetting mechanisms. The platform unifies Monte Carlo tree search with contribution-aware estimation to detect high-synergy expert combinations while maintaining privacy through partial data approaches. It scales across distributed computing environments, enabling complex collaborative tasks like materials discovery, product engineering and manufacturing process design, biomedical research, and drug development. The system supports multi-party economic rewards through systematic contribution effort, cost and importance tracking, while standardized interfaces manage security, privacy, and policy constraints across heterogeneous agents.

The invention, which relates to the technical field of medicine inventory management, discloses an intelligent medicine inventory management and optimization system comprising a demand prediction module, an inventory monitoring module, a purchase decision module and a medicine supply module. The demand prediction module is used for performing drug demand prediction according to historical sales data, seasonal factors and market trends; and analyzing and predicting by adopting a machine learning algorithm. According to the intelligent medicine inventory management and optimization system, based on a multi-objective optimization algorithm, in combination with the inventory turnover rate, the purchase cost and the medicine validity period, a scientific and reasonable purchase replenishment strategy is generated, including purchase time, quantity and supplier selection, and the scientificity and the accuracy of a purchase decision are improved; by integrating historical sales data, seasonal factors and market trends, demand prediction is performed by using a machine learning algorithm, and an accurate drug future demand trend prediction result can be generated.

The AI-enhanced cellular modeling and simulation platform is a computational system designed to enhance biomedical research and development and personalized medicine and wellness. This platform integrates simulation modeling, machine learning and artificial intelligence, multi-omics data, and sophisticated data fusion and decision-support techniques to create comprehensive models of cellular systems and processes across multiple scales. It enables researchers and clinicians to simulate complex biological interactions, predict disease progression, and design or optimize treatment strategies or medical devices with improved accuracy and efficacy. The system's architecture allows for integration of various components, including real-time data processing, federated learning, and quantum computing enhancements. From personalized drug discovery and cancer therapies to synthetic biology and epidemiological analysis, this platform offers powerful tools for understanding and manipulating cellular systems and bioengineered systems. By bridging the gap between molecular-level interactions between cells and materials and organism-wide effects, it enables significant advancements in healthcare and biological sciences.

There is provided herein compounds of formula (I), (XXI), (XXII) and (XXIII) as defined herein, and salts thereof, for use in the treatment of colorectal and / or lung cancer.

A fused ring compound, a pharmaceutical composition comprising same, and the use thereof. The compound has a structure as represented by formula (I), or is a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, a metabolite, a metabolic precursor, an isotope-substituted form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorph or a co-crystal thereof. The compound can be used for treating one or more cancers caused by KRAS mutation.

The invention relates to the technical field of medicines, and provides a use of a heterocyclic anti-tumor compound, in particular a use of the heterocyclic anti-tumor compound in the preparation of a medicine for preventing and / or treating tumors or cancers. The compound has a tri-heterocyclic structure (for example, a structure as shown in formula (B)), has a novel structure, and provides a new direction for the development of SOS1 inhibitor drugs.

Provided is a medicine for treating or preventing cancer that contains a first active ingredient and that is used in combination with a second active ingredient, wherein: the first active ingredient is a compound represented by formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; and the second active ingredient is GDC-6036 or a pharmaceutically acceptable salt thereof.

The present disclosure provides novel compounds useful as inhibitors of KRAS, in particular KRAS G12D and / or other KRAS G12 mutants, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.

The invention relates to a drug-disease relationship prediction method and system based on a dual-channel fusion knowledge graph. The method comprises the following steps: S1, constructing a biomedical fusion knowledge graph; s2, constructing a drug-disease sub-graph based on the biomedicine fusion knowledge graph; s3, constructing a dual-channel adaptive fusion feature module, and embedding a drug-disease sub-graph; s4, performing enhanced splicing on the drug-disease sub-graphs in the dual-channel fusion knowledge graph pre-embedded network, importing an edge-node iterative updating learning mechanism, training a spliced sub-graph relation perception learning network, and obtaining enhanced sub-graph feature embedding; and S5, utilizing the trained enhanced subgraph features to embed, calculate and output the prediction probability of the drug-disease relationship. According to the method, the semantic representation capability of the knowledge graph and the topological modeling advantages of the graph neural network are integrated, and efficient and accurate prediction of the drug-disease relationship is realized through multi-modal feature interaction, sub-graph enhancement and a dynamic sub-graph learning mechanism.

The invention relates to the field of antitumor drugs, in particular to a pharmaceutical composition of a KRAS G12C inhibitor and camptothecin and application of the pharmaceutical composition. The camptothecin and the KRAS G12C inhibitor are combined to play a synergistic effect, a DNA damage repair pathway is inhibited, a better inhibition effect is generated on tumor cells containing KRAS G12C mutation, the dosage required for achieving the same anti-tumor effect is greatly reduced, and the medication safety is improved.

The invention relates to an intelligent diagnosis and treatment method and system based on a knowledge graph and a large language model. The method comprises the steps of constructing a basic framework of a medical field knowledge graph based on collected medical field data, constructing multi-level knowledge graph expression, obtaining symptom description of a patient through multiple rounds of dialogues, diagnosing the patient and generating a diagnosis report, rechecking and adjusting the diagnosis report by a professional physician, and finally outputting the diagnosis report. The intelligent diagnosis and treatment system comprises a knowledge graph construction module, an intelligent question and answer system, an entity matching module, an intelligent diagnosis module, a doctor review and diagnosis report adjustment module, a diagnosis report output module and the like. And main diseases are screened, so that the coverage is wider. And three levels of knowledge maps are constructed, so that text matching with finer granularity can be carried out. The non-standardized expression of the patient is firstly converted into standardized medical terms through a large model, and drug allergy and the like are taken into consideration, so that the diagnosis accuracy is improved, and the diagnosis and treatment risk is reduced.

The present invention provides a method and intelligent agent for data collection and drug safety signal mining for PMS, which relates to the field of drug monitoring technology, including standardizing PMS data using a medical text pre-training model, and integrating drug molecular characteristics and clinical medication information to construct a multi-layer drug knowledge graph. A heterogeneous graph neural network with a time series feature extraction function is used to represent the graph, and the drug action mechanism rules are integrated into the training process to obtain a node vector representation of multi-dimensional information fusion. Based on the node vector representation, a multi-task learning framework is constructed to simultaneously complete the drug-adverse reaction association probability prediction and risk level prediction, and combine time series analysis to detect dynamic change characteristics to generate candidate signals. Finally, a hierarchical evaluation system is constructed to verify the candidate signal, and its reliability is confirmed in combination with clinical data, the target signal is output, the warning level is determined, and differentiated monitoring cycles and trigger thresholds are set to perform real-time risk warnings.

The invention discloses a method for in vitro slow release performance evaluation of a slow and controlled release preparation based on the overflow principle. A container with an upper outlet and a lower outlet is adopted to serve as a release tank, a to-be-detected medicine and a dissolution medium are placed in the release tank, a stirring device is adopted in the release tank to perform stirring, and the dissolution medium is added from the lower outlet of the release tank through a peristaltic pump; the dissolution medium dissolved with the medicine is taken away through the overflow from the upper outlet so as to offset medicine absorption or metabolism, and the slow and controlled release speed of the medicine, the total medicine overflow quantity and the total release amount are calculated by measuring the concentration of the medicine contained in the dissolution medium flowing out, the volume of the release tank and the overflow quantity. According to the method, the releasing degree of the slow and controlled release medicine can be evaluated accurately, the effective medicine release time of the slow and controlled release preparation is evaluated, and slow release performances of the slow and controlled release preparation are evaluated comprehensively.

The disclosure relates to an audible indicator in combination with a drug delivery device having a resilient force member capable of resting in either of two states. In a biased state, the resilient force member is biased and stores energy and in a relaxed state, the resilient force member is relaxed. The resilient force member releases the stored energy when changing from the biased state into the relaxed state, thereby generating an audible signal, wherein the resilient force member is supported by a retaining element in the biased state in order to prevent transition into the relaxed state.

Set forth are vascular valves and servovalves and methods of using the same that may be positioned in the circulatory system without interrupting blood flow to facilitate solid organ transplantation so as to reduce graft organ anoxia and degradation before and after harvesting and storage, thereby minimizing late-term cardiac allograft vasculopathy as a major cause of graft failure. Along the urinary tract, bypassing bladder-generated urge sensation by diverting urine directly from the ureters to a neobladder or collection bag alleviates intractable incontinence, nocturia, urethral syndrome, overactive bladder, dysuria, or frequency. Where the lower tract is missing, a prosthesis can thwart disease and preclude the degenerative metaplastic transition to carcinoma risked when gut is used to construct a conduit for urine, a neobladder, and / or high-maintenance stoma. Druglines to valves and servovalves can directly pipeline-target medication to nidi, anastomoses, or any other trouble spots.

An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

The disclosure relates to an audible indicator for use with a drug delivery device comprising a bistable resilient force member capable of residing in two states. In a biased state, the resilient force member is biased and stores energy In a relaxed state, the resilient force member is relaxed. The resilient force member releases the stored energy when transitioning from the biased state into the relaxed state, thereby generating an audible signal.

An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

The present disclosure provides an intelligent decision reasoning method for type-based diagnosis and treatment of a cardiovascular disease, a device, and a product, and relates to the medical field. The present disclosure adopts a risk factor mining model of a cardiovascular disease and a drug attribute association mining model of the cardiovascular disease to extract relevant information from cardiovascular data, achieving precise prediction of a fine-grained cardiovascular disease type and effectively promoting precision medicine. Based on a clinical diagnostic dataset and a clinical symptom diagnosis knowledge system of the cardiovascular disease, a type-based auxiliary diagnosis model of the cardiovascular disease is constructed, and intelligent decision reasoning is performed to obtain an association rule. This achieves efficient integration of type-based decision support of the cardiovascular disease and a medical convalescence knowledge base of the cardiovascular disease, and enhances quality of a cardiovascular medical convalescence association rule set.

The invention discloses a patient medication risk early warning method, and relates to the technical field of medication risk evaluation. The method comprises the following steps: acquiring multi-dimensional data such as age, past medical history, allergy history, clinical examination data and prescription data of a patient, extracting chronic disease diagnosis information from the multi-dimensional data, and carrying out standardized coding to generate a common disease combination tag; calling a preset disease weight system, and calculating a common disease severity score in combination with an age factor; extracting metabolism-related indexes to construct a drug metabolism capability feature vector of the patient; mapping the drug combination, the co-disease tag and the metabolic feature vector to a clinical drug knowledge base to generate a comprehensive conflict detection result; and generating corresponding early warning information based on the conflict detection result and a preset early warning rule base, wherein the rule base comprises a mapping relationship between the conflict type and the early warning level. According to the method, drug use risk early warning can be realized according to the multi-disease coexistence state of the patient, and the drug use safety is improved.

The invention relates to the technical field of cardiovascular disease treatment, and discloses a cardiovascular disease medical decision support method based on a large model, and the method comprises the steps: obtaining multi-modal cardiovascular disease medical data, constructing a multi-source heterogeneous data set, carrying out the preprocessing and feature fusion, and constructing a combined representation model based on the pre-training large model and the fusion of traditional and western medicine knowledge. And designing a hierarchical space-time diagram convolutional network to generate a dynamic physiological state code of the patient, and constructing a multi-target optimization decision tree to generate a treatment scheme containing western medicines, traditional Chinese medicine prescriptions and non-drug intervention. A federal learning framework is adopted to cooperatively train a local model, data security is guaranteed, a global model is optimized, and a curative effect attribution module is further arranged to correct decision deviation. According to the method, multi-modal data and traditional Chinese and western medicine knowledge are integrated, personalized treatment scheme generation is achieved, data safety is guaranteed, and the cardiovascular disease diagnosis and treatment level is improved.

The invention belongs to the technical field of medical resource intelligent management, and relates to a hospital comprehensive monitoring analysis method and platform based on artificial intelligence, and the method comprises the following steps: generating a medicine management basic data set; generating a primary prediction signal; adjusting a prediction weight according to the conflict level and outputting a reliable demand prediction instruction; a quantitative evaluation value reflecting the medicine turnover efficiency, the immediate pressure and the cost loss is calculated, and when the quantitative evaluation value exceeds a preset safety alert threshold value, an inventory abnormity alarm signal is generated; outputting an allocation strategy instruction containing the medicine flow direction, the allocation quantity and the time efficiency; and comparing a deviation value between the reliable demand prediction instruction and the allocation strategy instruction, and when the deviation value continuously exceeds a preset deviation threshold value, triggering an update prompt of the drug safety use limit rule base. The problem that demand prediction and clinical rule verification are separated in a traditional mode is solved.

To provide a medicine for treating a disease in a mammal.SOLUTION: Provided is a medicine for treating a disease in a mammal, comprising an expression cassette that is a first expression cassette comprising a chimeric gene operably linked to a first expression control element, the chimeric gene comprising a first portion comprising a minigene having an alternatively spliced exon and a second portion encoding a first RNA encoding a protein, the first portion being 5' to the second portion, the second portion lacking an initiation codon or start codon, the alternatively spliced exon comprising a translation initiation regulatory sequence, expression of the protein being controlled by inclusion of the alternatively spliced exon, and the medicine being used in combination with a small molecule splicing modifier that modulates splicing of the alternatively spliced exon.SELECTED DRAWING: Figure 1